Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Jingrong, Dong Yuan, Lan Yun, Chen Jing, Zhou Ying, Liu Jinjin, Yuan Dan, Lu Xinli, Guo Weigui, Zheng Minna, Yang Hong, Song Xiao, Liu Cong, Zhou Quanhua, Zheng Chenli, Guo Qi, Yang Xiaohui, Zhang Lincai, Ge Zhangwen, Liu Lifeng, Yu Fengting, Han Yang, Huang Huihuang, Hao Mingqiang, Ruan Yuhua, Wu Jianjun, Li Jianjun, Chen Qiang, Ning Zhen, Ling Xuemei, Zhou Chang, Liu Xuangu, Bai Jianyun, Gao Ya, Tong Xue, Zhou Kangping, Mei Fanghua, Yang Zhengrong, Wang Ao, Wei Wei, Qiao Ruijuan, Luo Xinhua, Huang Xiaojie, Wang Juan, Shen Xin, Hu Fengyu, Zhang Linglin, Tan Wei, Fan Jixiang, Tu Aixia, Yu Guolong, Fang Yong, He Shufang, Chen Xin, Wu Donglin, Zhang Xinhui, Xin Ruolei, He Xin, Ren Xianlong, Xu Conghui, Sun Yanming, Li Yang, Liu Guowu, Li Xiyao, Duan Junyi, Huang Tao, Shao Yiming, Feng Yi, Pan Qichao, Su Bin, Jiang Tianjun, Zhao Hongxin, Zhang Tong, Chen Faqing, Hu Bing, Wang Hui, Zhao Jin, Cai Kun, Sun Wei, Gao Baicheng, Ning Tielin, Liang Shu, Huo Yuqi, Fu Gengfeng, Li Feng, Lin Yi, Xing Hui, Lu Hongyan
Аннотация
METHODS: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations.
RESULTS: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH.
CONCLUSIONS: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.